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Abstract Aims/hypothesis: Measurement of plasma apo-
lipoprotein (Apo) B may improve prediction of cardio-
vascular risk, as it provides a measure of the total number
of atherogenic particles. The aim of this population-based
study was to compare the association of non-HDL-
cholesterol, ApoB and the ApoB:ApoA-I ratio with
cardiovascular mortality in people with type 2 diabetes.
Subjects and methods: We assessed the association of
lipids, lipoprotein lipids and apolipoproteins with 11-year
mortality from cardiovascular disease in the population-
based cohort of the Casale Monferrato Study (1,565
people with diabetes; median age 68.9 years), and
determined the effect of age (≤70 and >70 years) on
these relationships. Results: On the basis of 341 deaths
from cardiovascular disease in 10,809 person-years of
observation, there was a decreasing trend in risk adjusted
for multiple factors across quartiles of total cholesterol,
and LDL- and non-HDL-cholesterol in people aged
>70 years, but no trend in those aged ≤70 years. Age
did not affect the protective effect of HDL-cholesterol.
ApoB and ApoB:ApoA-I were associated with outcome in
people in both age groups independently of non-HDL-
cholesterol. After adjustment for multiple factors, includ-
ing non-HDL-cholesterol, the hazard ratios for ApoB:
ApoA-I in the upper vs lower quartile were 2.98 (95% CI
1.15–7.75; p for trend=0.009) for people aged ≤70 years
and 1.94 (95% CI 1.20–3.13; p for trend=0.003) for those
aged >70 years. Conclusions/interpretation: In this
cohort of Mediterranean subjects with diabetes, ApoB
and the ApoB:ApoA-I ratio were associated with cardio-
vascular disease mortality independently of non-HDL-
cholesterol. Our findings support the recommendation that
ApoB and ApoA-I should be measured routinely in all
people with diabetes, particularly in the elderly.
Keywords ApoB . Cohort . Epidemiology . Lipids .
Lipoproteins . Survey
Abbreviations AER: albumin excretion rate .
Apo: apolipoprotein . HR: Hazard ratio . ICD: International
classification of diseases
Introduction
The association between LDL-cholesterol and cardiovas-
cular disease in people aged <70 years of age is well
established [1]. This association is weaker in older people,
with an apparent paradoxical protective effect of high
concentrations of cholesterol in some observational studies
[2–7]. Measurement of plasma apolipoprotein (Apo) B and
ApoA-I improves the prediction of cardiovascular disease,
allowing identification of high-risk individuals who are not
identified by the standard lipid profile [8–10]. As there is
one molecule of ApoB per atherogenic particle, plasma
ApoB concentrations provide a measure of the total
number of atherogenic particles. A series of studies have
shown that ApoB is a more accurate index of atherogenic
risk than total cholesterol or LDL-cholesterol [10, 11], and,
in a multivariate analysis including hypertension, smoking,
central obesity, diabetes, psychosocial and dietary factors, a
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linear relationship was found between risk for cardiovas-
cular disease and ApoB:ApoA-I [12].
As small, dense LDL particles, which are strongly
associated with cardiovascular disease, contain less cho-
lesterol than large buoyant LDL, measurement of LDL-
cholesterol will clearly result in underestimation of the risk
due to LDL [13, 14]. To overcome this limitation and to
take into account the cholesterol in VLDL, the Expert
Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III)
recommended that non-HDL-cholesterol be used instead of
LDL-cholesterol for people with the metabolic syndrome
[15]. Non-HDL-cholesterol is the sum of all the cholesterol
in atherogenic lipoprotein particles (LDL, lipoprotein(a),
VLDL and intermediate-density lipoprotein). Since there is
a strong correlation between non-HDL-cholesterol and
ApoB, the Adult Treatment Panel III concluded that non-
HDL-cholesterol is an acceptable substitute for ApoB [15].
This choice was made in the absence of clinical data.
Since that time, a substantial number of reports have
indicated that ApoB and non-HDL-cholesterol are better
predictors than LDL-cholesterol in people with diabetes
[16–19]. Few studies have been conducted, however, to
compare non-HDL-cholesterol with ApoB [18, 19]; the
studies that have been reported were restricted to North
America, and the results were mixed. It would be
misleading to generalise the findings to other populations,
for a number of reasons. First, both the general populations
and people with diabetes living in the Mediterranean region
have a lower risk for cardiovascular disease than those
living in northern Europe and in the USA [20, 21]. Second,
there may have been selection bias in forming the cohorts.
Third, most of the studies were focused on middle-aged
people with diabetes, limiting an assessment of the effect of
age. In Mediterranean countries such as Italy, almost 50%
of people with diabetes are aged >70 years.
We previously identified a population-based cohort of
individuals with known diabetes, who are representative of
such people in Italy. This cohort has been followed
prospectively to determine 11-year mortality from all
causes and from cardiovascular disease [22–24]. As the
association of the ApoB:ApoA-I ratio has not been studied
in a population-based cohort of people with diabetes, the
aims of the analysis reported here were: (1) to investigate
the association between plasma lipids, lipoprotein lipids
and apolipoprotein with mortality from cardiovascular
disease; and (2) to assess whether age modifies any of these
relationships.
Subjects and methods
The study population comprised 1,565 patients with known
type 2 diabetes who were resident in 1988 in the town of
Casale Monferrato in north-west Italy (93,477 inhabitants).
These individuals were invited to undergo a baseline
examination in 1991–1992 to assess the prevalence of
micro- and macroalbuminuria and cardiovascular risk
factors and were followed up to 31 December 2001 [22].
Participants were identified from a diabetes clinic, general
practitioners (23.8% of the cohort), hospital discharge
records, prescriptions, and records of sales of reagent strips
and syringes. A high degree of ascertainment was achieved
(80%) [25]. Surveys conducted in Italy showed that the
participants were representative of patients with diabetes in
the country with regard to age, sex, duration of diabetes,
BMI and type of antidiabetic treatment [26].
As described in detail elsewhere, all patients were
interviewed and examined by trained investigators at
baseline [22]. All individuals gave informed consent and
the study was carried out in accordance with the
Declaration of Helsinki. Hypertension was defined as
systolic blood pressure ≥140 mmHg or diastolic blood
pressure ≥90 mmHg or treatment with antihypertensive
drugs. Venous blood samples were collected after fasting
for determination of triglycerides, total cholesterol, HDL-
cholesterol (enzymatic colorimetric method after precipi-
tation with Mn2+), ApoA-I, ApoB (turbidimetric method;
BM/Hitachi 717, BBR, Tokyo, Japan) and HbA1c (HPLC;
Daiichi, Menarini, Japan; laboratory reference range 3.8–
5.5%). LDL-cholesterol was calculated from Friedewald’s
formula for all except 44 people in the cohort who had
triglycerides >4.48 mmol/l (400 mg/dl). All laboratory
determinations were centralised. The albumin excretion
rate (AER) was calculated on the basis of the urinary
albumin concentration, measured in a single, timed,
overnight urine sample, analysed by the nephelometric
method (Behring Nephelometer Analyzer, Behring Insti-
tute, Marburg, Germany), after exclusion of urinary tract
infection, congestive heart failure and other known causes
of non-diabetic renal disease. Smoking was classified into:
never, ex-smoker if the patient had stopped smoking at
least 1 month before the visit, and smoker. For all patients
enrolled, the date of diagnosis was recorded. CHD was
defined from ECG abnormalities according to the Minne-
sota code, as described previously [27].
During the follow-up period (1991–2001), the partici-
pants were examined regularly during routine clinical
practice, three or four times per year, either at the diabetes
clinic or by general practitioners, with centralised measure-
ments of HbA1c. The average cumulative individual
concentrations of HbA1c during follow-up were calculated.
The relevant time scale for the analysis was time since
diagnosis of diabetes to death or to 31 December 2001,
whichever came first. Information on deaths was obtained
from the demographic files of towns of residence and
hospital discharge and autopsy records. Only one patient
was lost to follow-up. The underlying causes of death were
derived and coded by two of the authors according to the
ninth revision of the International Classification of
Diseases (ICD). Mortality rates were calculated by dividing
the number of deaths that occurred during the study period
by the number of person-years of observation.
All continuous variables were categorised into quartiles
of their distribution, except for age, which was categorised
into 5-year age groups (<60, 60–64, 65–69, 70–74, 75–79,
>79 years). The excess of risk of death from cardiovascular
disease and from all causes due to lipids, lipoprotein lipids
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and lipoprotein was expressed by hazard ratios (HR). Age-
and sex-adjusted HRs were calculated by multivariate Cox
proportional hazards modelling. Models included conven-
tional risk factors (age, sex, smoking, hypertension, CHD),
novel risk factors (AER, fibrinogen) and cumulative
individual average HbA1c during follow-up (time-depen-
dent variable). The HRs were also adjusted for referring
physician, as previous analyses of the Casale Monferrato
cohort identified this as a significant predictor of mortality
[24]. Given the time scale, all the models were also
adjusted for known duration of diabetes. We tested for
linear trends across categorical variables by entering a
single ordinal term into the Cox regression model. The
proportional hazard assumptions of explanatory variables
were assessed on the basis of Schoenfeld residuals. We
tested for the effect of age on lipids by including interaction
terms in the models. The likelihood ratio test was used to
assess the significance of variables. The p value was two-
sided; p<0.05 was considered to indicate statistical
significance. All analyses were performed with Stata
(Release 8.0, 2002; Stata, College Station, TX, USA).
Results
The baseline cohort comprised mainly older people (mean
age 68.7±10.7 years). Patients treated exclusively by
general practitioners constituted 23.8% of the cohort. The
median value for plasma LDL-cholesterol was 3.52 mmol/l
(136 mg/dl), and only 28.5% of patients had values
>4.14 mmol/l (160 mg/dl). A small minority (5.4%) was
being treated for hyperlipidaemia. As shown in Table 1, the
prevalence at the baseline examination of hypertension,
CHD and macroalbuminuria, lower BMI, plasma HbA1c,
total cholesterol, LDL-cholesterol and triglycerides values
and higher plasma concentrations of fibrinogen and HDL-
cholesterol was significantly higher in people aged
≥70 years than in those aged ≤70 years. No differences
between age groups were found in the mean values of
ApoA-I and ApoB. The prevalence of overweight (BMI
26–29 kg/m2) and obesity (BMI>29 kg/m2) were 34.3 and
30.2% in people aged ≤70 years and 29.0 and 18.2% in
those aged ≥70 years, respectively (p<0.0001).
During the 11-year follow-up, 341 of 685 deaths were due
to cardiovascular disease (ICD-9 codes 390–459) in 10,809
person-years of observation, giving a mortality rate for this
cause of 31.5/1,000 person-years (95% CI 28.4–35.1) and a
rate for all causes of 63.4/1,000 person-years (95% CI 58.8–
68.3). Table 2 shows the HRs for mortality from cardiovas-
cular disease according to plasma lipid profile, after
adjustment for age and sex (model 1), classical risk factors
(hypertension, smoking, CHD), novel risk factors (AER,
fibrinogen), cumulative average HbA1c during follow-up
and referring physician (model 2). Further adjustment for
non-HDL-cholesterol was performed in model 3.
Table 1 Characteristics of subjects with type 2 diabetes by age at baseline examination (1991–1992)
Characteristic Whole cohort (n=1,565) Aged ≤70 years (n=850) Aged >70 years (n=715) p valuea
Age (years) 68.7±10.7 60.7±7.0 78.1±5.3 <0.0001
Men (%) 679 (43.4%) 424 (49.9%) 255 (35.7%) <0.0001
Duration of diabetes (years) 10.8±7.0 9.9±6.2 11.9±7.7 <0.0001
BMI (kg/m2) 27.3±4.6 28.0±4.8 26.3±4.3 <0.0001
Hypertension (%) 1,309 (84.5%) 694 (82.0%) 615 (87.5%) 0.003
CHD 24.4% 22.0% 27.3% 0.02
AER (μg/min)
<20 762 (50.3%) 441 (53.5%) 321 (46.6%) 0.05
20–200 483 (31.9%) 259 (31.4%) 224 (32.5%)
>200 222 (18.7%) 125 (15.1%) 144 (20.9%)
Cared for by general practitioner (%) 369 (23.7%) 159 (18.8%) 210 (29.6%) <0.0001
Treatment
Diet 188 (12.2%) 90 (10.6%) 98 (14.0%) 0.11
Oral hypoglycaemics 1,096 (70.9%) 604 (71.6%) 492 (70.2%)
Insulin 261 (16.9%) 150 (17.8%) 111 (15.8%)
Fibrinogen (g/l) 3.6±0.9 3.6±0.9 3.7±0.9 0.008
HbA1c (%) 8.0±2.3 8.3±2.4 7.7±2.1 <0.0001
Total cholesterol (mmol/l) 5.79±1.26 5.89±1.30 5.67±1.20 0.008
LDL-cholesterol (mmol/l) 3.60±1.09 3.68±1.12 3.50±1.05 0.01
HDL-cholesterol (mmol/l) 1.41±0.42 1.39±0.42 1.44±0.41 0.04
Triglycerides (mmol/l)b 1.52 (1.06–2.05) 1.50 (1.09–2.09) 1.37 (1.03–1.89) 0.003
ApoA-I (mg/dl) 134.8±34.5 134.5±34.7 135.1±34.4 0.72
ApoB (mg/dl) 104.3±37.4 104.5±37.9 104.1±36.8 0.84
aFor comparison between age groups
bGeometric mean (interquartile range)
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Table 2 Mortality rates from cardiovascular disease in subjects of the study cohort with type 2 diabetes, classified by plasma lipid
concentrations at baseline examination (1991–1992)
Plasma lipid Mortality rate from cardiovascular disease
(death rate/1,000 person-years)
HRa (95% CI) HRb (95% CI) HRc (95% CI)
Total cholesterol (mmol/l)
<4.91 87 36.6 1.00 1.00
4.91–5.69 88 32.3 0.89 (0.66–1.20) 0.83 (0.59–1.18)
5.70–6.49 83 29.3 0.80 (0.59–1.09) 0.80 (0.56–1.14)
>6.49 73 25.9 0.78 (0.57–1.08) 0.67 (0.46–0.99)
p for trend 0.11 0.05
LDL-cholesterol (mmol/l)
<2.89 82 34.0 1.00 1.00
2.89–3.53 84 32.2 0.96 (0.71–1.31) 0.90 (0.63–1.28)
3.54–4.29 79 28.5 0.92 (0.67–1.25) 0.91 (0.63–1.29)
>4.29 70 26.7 0.91 (0.66–1.27) 0.77 (0.53–1.12)
p for trend 0.49 0.20
HDL-cholesterol (mmol/l)
<1.16 104 39.0 1.00 1.00
1.16–1.37 76 27.4 0.67 (0.50–0.90) 0.79 (0.56–1.11)
1.38–1.63 75 28.7 0.67 (0.49–0.90) 0.64 (0.45–0.92)
>1.63 70 26.4 0.55 (0.41–0.75) 0.66 (0.47–0.95)
p for trend 0.0003 0.01
Non-HDL-cholesterol (mmol/l)
<3.57 86 33.5 1.00 1.00
3.57–4.25 81 31.7 0.96 (0.71–1.31) 0.87 (0.61–1.24)
4.26–5.12 81 28.3 0.93 (0.68–1.27) 0.96 (0.68–1.35)
>5.12 77 28.4 1.03 (0.75–1.41) 0.79 (0.54–1.15)
p for trend 0.99 0.32
LDL:HDL (mmol/l)
<1.98 70 26.4 1.00 1.00
1.98–2.56 76 29.6 1.12 (0.81–1.56) 1.00 (0.68–1.46)
2.57–3.34 84 31.8 1.37 (1.00–1.88) 1.26 (0.87–1.82)
>3.34 85 33.1 1.60 (1.16–2.20) 1.25 (0.86–0.81)
p for trend 0.003 0.13
Triglycerides (mmol/l)
<1.06 84 32.4 1.00 1.00 1.00
1.06–1.43 74 27.4 0.89 (0.65–0.23) 0.85 (0.59–1.23) 0.86 (0.59–1.24)
1.44–2.03 88 32.6 1.17 (0.87–1.58) 0.94 (0.66–1.35) 0.98 (0.68–1.41)
>2.03 84 30.7 1.09 (0.80–1.49) 0.89 (0.62–1.28) 0.96 (0.65–1.42)
p for trend 0.98 0.70 0.99
ApoA-I (mg/dl)
<111 91 34.6 1.00 1.00 1.00
112–129 88 32.9 0.99 (0.74–1.33) 0.99 (0.70–1.39) 0.99 (0.70–1.40)
130–152 73 28.1 0.72 (0.52–0.98) 0.82 (0.57–1.18) 0.83 (0.58–1.19)
>152 68 24.5 0.65 (0.47–0.90) 0.78 (0.55–1.12) 0.79 (0.55–1.12)
p for trend 0.002 0.12 0.13
ApoB (mg/dl)
<77 76 26.9 1.00 1.00 1.00
77–101 68 24.5 0.99 (0.72–1.39) 1.12 (0.75–1.67) 1.24 (0.82–1.88)
102–126 88 34.8 1.44 (1.05–1.96) 1.59 (1.10–2.29) 1.80 (1.22–2.64)
>126 88 34.6 1.30 (0.96–1.78) 1.48 (1.02–2.14) 1.77 (1.18–2.66)
p for trend 0.034 0.012 0.001
ApoB:ApoA-I (mg/dl)
<0.58 66 25.3 1.10 1.00 1.00
0.58–0.76 69 22.9 1.14 (0.81–1.61) 1.09 (0.74 (1.63) 1.22 (0.81–1.84)
0.77–0.96 88 34.4 1.59 (1.15–2.20) 1.59 (1.09–2.33) 1.84 (1.23–2.74)
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Decreasing trends in HRs adjusted for multiple factors
were found across quartiles of total cholesterol, LDL-
cholesterol and non-HDL-cholesterol; statistical signifi-
cance was reached only for total cholesterol, with HRs for
the upper vs the lower quartile of 0.67 (95% CI 0.46–0.99,
p for trend=0.05) for mortality from cardiovascular disease
and 0.60 (95% CI 0.46–0.79, p for trend<0.0001) for
mortality from all causes. The HRs were similar with
regard to non-HDL-cholesterol: 0.79 (95% CI 0.54–1.15, p
for trend=0.32) for mortality from cardiovascular disease
and 0.70 (95% CI 0.54–0.91, p for trend=0.004) for
mortality from all causes. Decreasing trends across
quartiles of HDL-cholesterol (p=0.01 and p=0.003,
model 2) and ApoA-I (p=0.13 and p=0.03, model 3)
were also found for mortality from both cardiovascular
disease and all causes, respectively. A significant rising
trend in age- and sex-adjusted HRs for mortality from
cardiovascular disease was found across quartiles of the
LDL-cholesterol:HDL-cholesterol ratio (model 1,
p=0.003), whereas in the model with adjustment for
multiple factors, the HR for the upper quartile decreased
from 1.60 to 1.25 (p for trend=0.13). No associations were
found between triglycerides concentrations and mortality
from either cardiovascular disease or all causes.
ApoB and non-HDL-cholesterol concentrations were
highly correlated (r=0.49, p<0.0001). Nevertheless, their
association with the outcome was markedly different in
multivariate analyses. An increasing trend of adjusted HRs
was seen across ApoB quartiles (p=0.012, model 2), with
values of 1.59 (95% CI 1.10–2.92) and 1.48 (95% CI 1.02–
2.14) for the upper vs the lower quartile. The finding that
the HR in the fourth quartile was lower than that in the third
is probably due to survival bias, as at baseline we recruited
a cohort of people with prevalent rather than incident
diabetes. Whereas the HRs for other lipids were virtually
unchanged by adjustment for cumulative HbA1c during
follow-up, the HRs for ApoB appeared to be negatively
confounded by glycaemic control, as the HR increased in
the upper quartiles, from 1.47 to 1.59 and from 1.35 to
1.48, after further adjustment for cumulative individual
HbA1c. The association of ApoB with mortality from
cardiovascular disease was seen even after adjustment for
non-HDL-cholesterol: HR=1.80 (95% CI 1.22–2.64) for
the third quartile and 1.77 (95% CI 1.18–2.66) for the
fourth quartile (p for trend=0.001, model 3). ApoB had no
association with mortality from all causes (HR=1.03; 95%
CI 0.79–1.34 for the upper quartile). As shown in Table 2,
the highest mortality risk was seen for ApoB:ApoA-I
(HR=1.59 [95% CI 1.09–2.33] for the third quartile, and
1.69 [95% CI 1.16–2.46] for the fourth quartile; p for
trend=0.001, model 2); after adjustment for non-HDL-
cholesterol, further increases in HR were seen (HR=1.84
[95% CI 1.23–2.74] and HR=2.06 [95% CI 1.36–3.11]; p
for trend <0.0001, model 3).
As the interaction terms with age were significant, we
stratified our analyses by age at baseline examination (≤70
vs >70 years) (Tables 3 and 4). In general, most changes in
risk were seen in people >70 years; however, even in those
>70 years, ApoB and ApoB:ApoA-I were independently
associated with mortality after adjustment for non-HDL-
cholesterol. In this analysis, the apparent protective effect
of non-HDL-cholesterol on mortality from cardiovascular
disease was seen only in the oldest age group. The HRs for
the upper quartiles were 1.52 (95% CI 0.72–3.23, p for
trend=0.25) for people ≤70 years and 0.58 (95% CI 0.36–
0.93, p for trend=0.03) for those >70 years. The respective
values for ApoB (model 3) were 2.86 (95% CI 1.22–6.67, p
for trend=0.005) and 1.50 (95% CI 0.93–2.41, p for
trend=0.04). The ApoB:ApoA-I ratio was negatively
confounded by non-HDL-cholesterol in older people, as
shown by significant association in higher quartiles after
adjustment for non-HDL-cholesterol: HR=1.94 (95% CI
1.20–3.13, p for trend=0.003).
The estimated HRs were not modified by further
adjustment for treatment of diabetes or hyperlipidaemia
(5.4% of the cohort), for BMI, or for exclusion of people
who died within 1 year of follow-up.
Discussion
In this population-based cohort of patients with type 2
diabetes in a Mediterranean country, who have a lower risk
of cardiovascular disease than people living in northern
Europe and the USA, ApoB and the ApoB:ApoA-I ratio
were associated with mortality from cardiovascular disease
independently of non-HDL-cholesterol. These associations
were seen in people <70 years of age and were independent
of classical cardiovascular risk factors (sex, smoking,
hypertension, CHD), novel risk factors (AER, fibrinogen)
and individual average cumulative HbA1c during follow-
up. In people aged >70 years, ApoB and ApoB:ApoA-I
were still associated with mortality from cardiovascular
disease, but more weakly than for people aged ≤70 years.
Table 2 (continued)
Plasma lipid Mortality rate from cardiovascular disease
(death rate/1,000 person-years)
HRa (95% CI) HRb (95% CI) HRc (95% CI)
>0.96 97 39.0 1.86 (1.36–2.56) 1.69 (1.16–2.46) 2.06 (1.36–3.11)
p for trend <0.0001 0.001 <0.0001
aAdjusted for age and sex
bAdjusted for age, sex, hypertension, smoking, CHD, AER, fibrinogen, cumulative average individual HbA1c and referring physician
cAdjusted for the above (b) and non-HDL-cholesterol
941
Non-HDL-cholesterol appeared to have a protective effect
against mortality from all causes and from cardiovascular
disease. In contrast, a decreasing trend in mortality risk was
seen with increasing plasma values of HDL-cholesterol in
both age groups.
Ours is the first population-based study conducted to
compare ApoB and non-HDL-cholesterol values in white
people of European origin with diabetes. The Strong Heart
Study, which addressed only American Indians, showed
that non-HDL-cholesterol is a better predictor of cardio-
vascular morbidity than LDL-cholesterol [17]. Two further
studies of people with diabetes in the USA, who were free
of cardiovascular disease at baseline, comprised 921
female nurses aged <65 years [18] and 746 male health
professionals aged 46–81 years [19]. In both studies, non-
HDL-cholesterol was considered a better predictor of
cardiovascular disease than ApoB. In contrast, the
AMORIS study of more than 170,000 people in Sweden
indicated that ApoB and ApoA-I are better predictors than
lipoprotein lipids overall and are of greatest value in
predicting CHD in people with normal or low LDL-
cholesterol values and in the elderly [11].
Although the previous studies were well conducted and
analysed, their results cannot be extrapolated to Mediterra-
nean populations, who are characterised by a lower risk of
cardiovascular disease, attributed mainly to the Mediterra-
nean diet. Furthermore, people with diabetes in this
population have lower excess mortality from cardiovascu-
lar disease than the general population (standardised
mortality ratio 1.42 in the Verona Diabetes Study and
1.35 in the Casale Monferrato Study) [20, 21] and are older
at onset of the disease, with a median age of 70 years in
Italian cohorts of prevalent cases. The Casale Monferrato
cohort is representative of Italian patients with diabetes as
regards age, sex, duration of disease, BMI and type of
antidiabetic treatment [26]. Moreover, we recruited a
population-based cohort of patients with diabetes and
could therefore take into account differences between
patients cared for exclusively by general practitioners and
those treated in diabetes clinics [28]. Other strengths of the
present study are the completeness of ascertainment of the
cohort, centralised measurements and long follow-up for
survival, resulting in 6,837 person-years of observation for
people aged ≤70 years and 3,972 person-years for those
aged ≥70 years.
Our study adds to knowledge about the relationship
between lipids, lipoproteins and cardiovascular risk,
demonstrating an association of ApoB and ApoB:ApoA-I
in Mediterranean people with diabetes. ApoB predicts
mortality from cardiovascular disease even in the presence
of normal or low non-HDL-cholesterol values. A detailed
study has shown that measurements of ApoB provide a
better estimate of small dense LDL particles, which are not
detected by simple measurement of non-HDL-cholesterol
[14]. Our findings are therefore consistent with those of
others [8].
There is increasing evidence that the relationship
between traditional risk factors and cardiovascular disease
changes with advancing age. Whereas low HDL-choles-
terol is predictive of cardiovascular disease even among
people >70 years old [29, 30], observational studies in the
elderly have either shown no predictive effect of plasma
LDL-cholesterol or a protective effect of higher concentra-
tions [3–6]. In a large population-based cohort of elderly
people in the USA, 20% of whom had diabetes, the
protective effect of higher concentrations of total choles-
Table 3 HRs for mortality from cardiovascular disease in subjects
of the study cohort with type 2 diabetes, classified by age at baseline
examination and plasma lipid concentrations






4.91–5.69 0.74 (0.33–1.67) 0.87 (0.58–1.29)
5.70–6.49 1.32 (0.67–2.62) 0.60 (0.39–0.91)
>6.49 0.99 (0.49–2.02) 0.55 (0.34–0.88)
p for trend 0.66 0.003
LDL-cholesterol (mmol/l)
<2.89 1.00 1.00
2.89–3.53 0.71 (0.31–1.63) 0.96 (0.64–1.42)
3.54–4.29 1.00 (0.49–2.06) 0.84 (0.56–1.28)
>4.29 1.03 (0.52–2.08) 0.59 (0.38–0.95)
p for trendb 0.70 0.03
HDL-cholesterol (mmol/l)
<1.16 1.00 1.00
1.16–1.37 0.62 (0.32–1.22) 0.91 (0.61–1.37)
1.38–1.63 0.74 (0.39–1.40) 0.58 (0.37–0.90)
>1.63 0.71 (0.34–1.49) 0.64 (0.42–0.96)




3.57–4.25 1.25 (0.54–2.87) 0.80 (0.53–1.19)
4.26–5.12 1.47 (0.69–3.12) 0.80 (0.54–1.19)
>5.12 1.52 (0.72–3.23) 0.58 (0.36–0.93)
p for trend 0.25 0.03
LDL:HDL (mmol/l)
<1.98 1.00 1.00
1.98–2.56 1.65 (0.73–3.73) 0.86 (0.55–1.34)
2.57–3.34 1.48 (0.64–3.40) 1.26 (0.83–1.91)
>3.34 1.29 (0.57–2.97) 1.29 (0.84–1.98)
p for trend 0.80 0.11
Triglycerides (mmol/l)
<1.06 1.00 1.00
1.06–1.43 0.75 (0.34–1.64) 0.87 (0.57–1.32)
1.44–2.03 0.68 (0.32–1.45) 1.08 (0.72–1.12)
>2.03 1.24 (0.63–2.44) 0.77 (0.49–1.20)
p for trend 0.39 0.46
aAdjusted for age, sex, hypertension, smoking, CHD, AER,
fibrinogen, cumulative average individual HbA1c and referring
physician
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terol disappeared after adjustment for markers of poor
health, suggesting confounding effects of comorbidity and
frailty [5]. In the Honolulu Heart Program, in which 3,572
Japanese American men were followed-up prospectively
for 20 years, significantly decreasing age-adjusted mortal-
ity rates were found for the upper vs the lower quartiles of
cholesterol concentrations, particularly in men with
persistently low cholesterol values in consecutive exam-
inations [3]. Our results are therefore consistent with those
of other observational studies, including the AMORIS
study [11], showing lower predictive power of cholesterol
levels on cardiovascular events in the elderly than in
younger age groups. From a practical point of view,
however, trials have shown that even the elderly benefit
greatly from treatment to reduce high cholesterol concen-
trations: this treatment should be prescribed in elderly
diabetic people with hypercholesterolaemia [2]. Our
findings could be due, at least in part, to the effect of
frailty and comorbidities. However, neither adjusting for
BMI nor the removing of the deaths that occurred within
the first year of follow-up modified our results.
In conclusion, the results of this population-based study
indicate that in people living in the Mediterranean region
who have diabetes, ApoB and ApoB:ApoA-I are asso-
ciated with mortality from cardiovascular disease indepen-
dently of non-HDL-cholesterol. Our findings support the
recommendation that measurement of ApoB and ApoA-I
should be added to the lipid profile assessment of people
with diabetes, particularly for the elderly, for whom
predictions based only on total cholesterol and non-HDL-
cholesterol values could be misleading. Elderly people
with diabetes and high concentrations of ApoB and ApoB:
ApoA-I should be considered at high risk, even if their
LDL-cholesterol values are low or normal.
Acknowledgements We thank the patients, the nurses at the
diabetes clinic, the diabetologists and the general practitioners for
long-standing collaboration in this study. We would like to thank A.
D. Sniderman for his useful advice. The Casale Monferrato Study is
supported by grants from the Ministry of Education, University and
Scientific and Technologic Research, Italy. We also acknowledge the
contribution of the Italian Association for Cancer Research and the
Compagnia San Paolo/FIRMS.
References
1. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of
recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III Guidelines. J Am Coll
Cardiol 44:720–732
2. Dornbrook-Lavender KA, Pieper JA, Roth MT (2003) Primary
prevention of coronary heart disease in the elderly. Ann
Pharmacother 37:1654–1663
3. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD
(2001) Cholesterol and all-cause mortality in elderly people
from the Honolulu heart program. A cohort study. Lancet
358:351–355
4. Fried L, Kronmal RA, Newman AB et al (1998) Risk factors
for 5-year mortality in older adults. The Cardiovascular Health
Study. JAMA 279:585–592
5. Corti MC, Guralnik JM, Salive ME et al (1997) Clarifying the
direct relation between total cholesterol levels and death from
coronary heart disease in older persons. Ann Intern Med
126:753–760
6. Krumholz HM, Seeman TE, Merrill SS et al (1994) Lack of
association between cholesterol and coronary heart disease
mortality and morbidity and all-cause mortality in persons older
than 70 years. JAMA 272:1335–1340
Table 4 HRs for mortality from cardiovascular disease in subjects of the study cohort with type 2 diabetes, classified by age at baseline
examination and plasma apolipoprotein concentrations
Plasma apolipoprotein Age ≤70 years Age >70 years
HRa (95% CI) HRb (95% CI) HRa (95% CI) HRb (95% CI)
ApoA-I (mg/dl)
<111 1.00 1.00 1.00 1.00
112–129 0.64 (0.34–1.20) 0.63 (0.34–1.19) 1.16 (0.77–1.77) 1.18 (0.77–1.79)
130–152 1.08 (0.55–2.13) 1.09 (0.55–2.16) 0.75 (0.48–1.17) 0.74 (0.48–1.15)
>152 0.69 (0.33–1.43) 0.68 (0.33–1.41) 0.79 (0.52–1.19) 0.78 (0.52–1.19)
p for trend 0.55 0.53 0.10 0.09
ApoB (mg/dl)
<77 1.00 1.00 1.00 1.00
77–101 1.40 (0.63–3.13) 1.33 (0.56–3.15) 1.03 (0.65–1.65) 1.18 (0.73–1.91)
102–126 1.96 (0.89–4.32) 1.94 (0.84–4.49) 1.44 (0.94–2.21) 1.69 (1.08–2.63)
>126 2.92 (1.34–6.37) 2.86 (1.22–6.67) 1.15 (0.75–1.77) 1.50 (0.93–2.41)
p for trend 0.003 0.005 0.33 0.04
ApoB:ApoA-I (mg/dl)
<0.58 1.00 1.00 1.00 1.00
0.58–0.76 1.59 (0.61–4.12) 1.52 (0.58–4.00) 1.10 (0.70–1.73) 1.31 (0.82–2.07)
0.77–0.96 2.06 (0.81–5.25) 1.99 (0.76–5.18) 1.50 (0.98–2.29) 1.85 (1.18–2.90)
>0.96 3.06 (1.23–7.62) 2.98 (1.15–7.75) 1.42 (0.92–2.19) 1.94 (1.20–3.13)
p for trend 0.006 0.009 0.05 0.003
aAdjusted for age, sex, hypertension, smoking, CHD, AER, fibrinogen, cumulative average individual HbA1c and referring physician
bAdjusted for the above (a) and non-HDL-cholesterol
943
7. Dornbrook-Lavender KA, Pieper JA, Roth MT (2003) Primary
prevention of coronary heart disease in the elderly. Ann
Pharmacother 37:1654–1663
8. Sniderman AD (2002) How, when, and why to use apolipo-
protein B in clinical practice. Am J Cardiol 90(Suppl):48i–54i
9. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres
JP, Lamarche B (2003) Concordance/discordance between
plasma apolipoprotein B levels and the cholesterol indexes of
atherosclerotic risk. Am J Cardiol 91:1173–1177
10. Sniderman AD, Furberg CD, Keech A et al (2003) Apolipo-
proteins versus lipids as indices of coronary risk and as targets
for statin treatment. Lancet 361:777–780
11. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner
E (2001) High apolipoprotein B, low apolipoprotein A-I, and
improvement in the prediction of fatal myocardial infarction
(AMORIS study): a prospective study. Lancet 358:2026–2033
12. Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially
modifiable risk factors associated with myocardial infarction in
52 countries (the INTERHEART study): case-control study.
Lancet 364:912–914
13. Sniderman AD (2003) Non-HDL cholesterol versus apolipo-
protein B in diabetic dyslipoproteinemia: alternatives and
surrogates versus the real thing. Diabetes Care 26:2207–2208
14. Wagner AM, Perez A, Zapico E, Ordonez-Llanos J (2003) Non-
HDL cholesterol and apolipoprotein B in the dyslipidemic
classification of type 2 diabetic patients. Diabetes Care
26:2048–2051
15. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) (2001)
Executive summary of the Third Report of the National
Cholesterol Education Program (NCEP), Expert Panel on
Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults (Adult Treatment Panel III). JAMA 285:
2486–2497
16. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V,
Laakso M (1997) Dyslipidemia and hyperglycemia predict
coronary heart disease events in middle-aged patients with
NIDDM. Diabetes 46:1354–1359
17. Lu W, Resnick HE, Jablonski KA et al (2003) Non-HDL
cholesterol as a predictor of cardiovascular disease in type 2
diabetes: the Strong Heart Study. Diabetes Care 26:16–23
18. Schulze MB, Shai I, Manson JE et al (2004) Joint role of non-
HDL cholesterol and glycated haemoglobin in predicting future
coronary heart disease events among women with type 2
diabetes. Diabetologia 47:2129–2136
19. Jiang R, Schulze MB, Li T et al (2004) Non-HDL cholesterol
and apolipoprotein B predict cardiovascular disease events
among men with type 2 diabetes. Diabetes Care 27:1991–1997
20. Bruno G, Merletti F, Boffetta P et al (1999) Impact of
glycaemic control, hypertension and insulin treatment on
general and cause-specific mortality: an Italian population-
based cohort of type II (non-insulin-dependent) diabetes
mellitus. Diabetologia 42:297–301
21. Brun E, Nelson RG, Bennett PH et al (2000) Verona Diabetes
Study: diabetes duration and cause-specific mortality in the
Verona Diabetes Study. Diabetes Care 23:1119–1123
22. Bruno G, Cavallo-Perin P, Bargero G et al (1996) Prevalence
and risk factors for micro- and macroalbuminuria in an Italian
population-based cohort of non-insulin-dependent diabetic
subjects. Diabetes Care 19:43–47
23. Bruno G, Merletti F, Biggeri A et al (2005) Metabolic
syndrome as predictor of all-causes and cardiovascular mortal-
ity in type 2 diabetes: the Casale Monferrato Study. Diabetes
Care 27:2689–2694
24. Bruno G, Merletti F, Biggeri A et al (2005) Fibrinogen and
albumin excretion rate are major independent predictors of 11-
year cardiovascular mortality in type 2 diabetes: the Casale
Monferrato Study. Diabetologia 48:427–434
25. Bruno G, LaPorte R, Merletti F, Biggeri A, McCarty D, Pagano
G (1994) National diabetes programmes: application of
capture-recapture to “count” diabetes? Diabetes Care 17:
548–556
26. Garancini MP (1996) L’epidemiologia del diabete non-
insulino-dipendente e della ridotta tolleranza al glucosio. In:
Vaccaro O, Bonora E, Bruno O, Garancini MP, Muntoni S,
Società Italiana di Diabetologia Gruppo di Studio di Epide-
miologia e Statistica (eds) Il Diabete in Italia. Kurtis, Milan pp
17–30
27. Veglio M, Bruno G, Borra M et al (2002) Prevalence of
increased QT interval duration and dispersion in type 2 diabetic
patients and its relationship with coronary heart disease: a
population-based cohort. J Intern Med 251:317–324
28. Bruno G, Cavallo-Perin P, Bargero G et al (1999) Cardiovas-
cular risk profile of type 2 diabetic patients cared for by general
practitioners or by a diabetes clinic: a population-based study.
J Clin Epidemiol 52:413–417
29. Curb JD, Abbott RD, Rodriguez BL et al (2004) High density
lipoprotein cholesterol and the risk of stroke in elderly men.
The Honolulu Heart Program. Am J Epidemiol 160:150–157
30. Corti MC, Guralnik JM, Salive ME et al (1995) HDL
cholesterol predicts coronary heart disease mortality in older
persons. JAMA 274:539–544
944
